AMPH (Amphastar Pharmaceuticals) Asset Impairment Charge: $0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMPH Amphastar Pharmaceuticals Inc AMPH
85 GF Score
Price $23.78
GF Value $36.12
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Amphastar Pharmaceuticals Asset Impairment Charge?

Amphastar Pharmaceuticals AMPH +0.93% 85 Asset Impairment Charge is $0.0 Mil as of Jun. 2026. GuruFocus rates AMPH with a GF Score™ of 85/100 and a GF Value™ of $36.12 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Amphastar Pharmaceuticals's Asset Impairment Charge for the three months ended in Jun. 2026 was $0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 was $0.0 Mil.

Amphastar Pharmaceuticals Asset Impairment Charge Related Terms

Amphastar Pharmaceuticals Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Amphastar Pharmaceuticals's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amphastar Pharmaceuticals Asset Impairment Charge Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 2.70 0.00 0.00

Amphastar Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
AMPH
85GF Score
Amphastar Pharmaceuticals Inc AMPH
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amphastar Pharmaceuticals Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

What does a Asset Impairment Charge of $0.0 Mil mean?
Amphastar Pharmaceuticals (AMPH) has a Asset Impairment Charge of $0.0 Mil as of Jun. 2026.
Is Amphastar Pharmaceuticals' Asset Impairment Charge too high?
Amphastar Pharmaceuticals' current Asset Impairment Charge is $0.0 Mil. Overall, Amphastar Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Asset Impairment Charge compare to PCRX and COLL?
Amphastar Pharmaceuticals' Asset Impairment Charge of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Drug Manufacturers company?
A good Asset Impairment Charge depends on the Drug Manufacturers industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Amphastar Pharmaceuticals's current Asset Impairment Charge is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $36.12, compared to a current price of $23.78 — trading 34.2% below its estimated fair value. The current Asset Impairment Charge is $0.0 Mil. Amphastar Pharmaceuticals' overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Asset Impairment Charge is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued. The current stock price of $23.78 is trading 34.2% below its estimated GF Value™ of $36.12. GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for AMPH:

  • Asset Impairment Charge: $0.0 Mil
  • GF Value™: $36.12 vs. price of $23.78 (34.2% below fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amphastar Pharmaceuticals Business Description

Other Exchanges 29A:Germany
Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
85GF Score

Get the complete analysis for AMPH

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.78
Price
$36.12
GF Value